Robbins LLP is informing investors of a class action lawsuit against Corcept Therapeutics Inc. (NASDAQ: CORT) for allegedly misleading investors about its new product candidate, relacorilant. The company’s stock price declined significantly after the FDA issued a Complete Response Letter for relacorilant’s New Drug Application due to concerns about effectiveness. Investors who purchased Corcept stock between October 31, 2024, and December 30, 2025, may be eligible to participate in the lawsuit.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Investor Alert: Robbins LLP Informs Investors of the Corcept Therapeutics Inc. Class Action Lawsuit
Robbins LLP is informing investors of a class action lawsuit against Corcept Therapeutics Inc. (NASDAQ: CORT) for allegedly misleading investors about its new product candidate, relacorilant. The company’s stock price declined significantly after the FDA issued a Complete Response Letter for relacorilant’s New Drug Application due to concerns about effectiveness. Investors who purchased Corcept stock between October 31, 2024, and December 30, 2025, may be eligible to participate in the lawsuit.